{
    "pmcid": "11515141",
    "qa_pairs": {
        "What are the origins of nanobodies as described in the paper?": [
            "Nanobodies are derived from heavy-chain-only antibodies found in camelids and cartilaginous fish.",
            "Nanobodies are derived from light-chain antibodies found in rodents and primates.",
            "Nanobodies are derived from full-length antibodies found in birds and reptiles.",
            "Nanobodies are derived from single-chain antibodies found in amphibians and insects."
        ],
        "What is a notable feature of nanobodies that enhances their suitability for therapeutic and diagnostic applications?": [
            "They offer high solubility, stability, and resistance to aggregation.",
            "They have a large molecular size and complex structure.",
            "They require high production costs and specialized facilities.",
            "They exhibit low antigen-binding affinity and specificity."
        ],
        "What is a potential administration route for nanobodies in SARS-CoV-2 applications mentioned in the paper?": [
            "Intranasal administration",
            "Intravenous administration",
            "Oral administration",
            "Subcutaneous administration"
        ],
        "What strategy is suggested to overcome the challenge of SARS-CoV-2 viral mutation and escape?": [
            "Combining individual nanobodies that bind to different spike protein sites.",
            "Using a single nanobody with broad-spectrum activity.",
            "Relying on natural immunity to prevent viral escape.",
            "Developing vaccines that target non-spike proteins."
        ],
        "Which nanobodies are highlighted for their ability to neutralize SARS-CoV-2, including Omicron strains?": [
            "Nb-H6 and Nb4",
            "Nb-A1 and Nb-B2",
            "Nb-C3 and Nb-D4",
            "Nb-E5 and Nb-F6"
        ]
    }
}